Safety Study of XP12B in Women With Menorrhagia

This study has been completed.
Sponsor:
Information provided by:
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00113568
First received: June 8, 2005
Last updated: June 9, 2010
Last verified: June 2010

June 8, 2005
June 9, 2010
June 2005
May 2009   (final data collection date for primary outcome measure)
  • Number of Subjects With at Least One Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    An adverse event is any untoward, undesired, unplanned clinical event in the form of signs. symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study with a sponsor study drug, regardless of causal relationship.
  • Number of Subjects With at Least One Possibly Treatment-Related Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    The causal relation between an adverse event and the study drug was determined by the investigator on the basis of his or her clinical judgment. A possibly treatment-related adverse event is an event that may be explained by administration of the study drug or by the subjects's clinical state or other agents/therapies.
  • Number of Subjects With at Least One Probably Treatment-Related Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    The causal relation between an adverse event and the study drug was determined by the investigator on the basis of his or her clinical judgment. A probably treatment-related adverse event is an event most likely to be explained by administration of the study drug rather than the subjects's clinical state or other agents/therapies.
  • Number of Subjects With at Least One Definitely Treatment-Related Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    The causal relation between an adverse event and the study drug was determined by the investigator on the basis of his or her clinical judgment. A definitely treatment-related adverse event is an event that can be fully explained by administration of the study drug.
  • Number of Subjects With at Least One Serious Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    A serious adverse event (SAE) is any adverse event (AE) occurring at any dose that meets 1 or more of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in a persistent or significant disability or incapacity; results in cancer; results in a congenital anomaly or birth defect. Important medical events not described above may be considered SAEs when based on appropriate medical judgment.
  • Number of Subjects With at Least One Life-Threatening Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    A life-threatening AE is any AE that places the subject at immediate risk of death from the event as it occurred.
  • Number of Subjects With Adverse Events That Led to Discontinuation From the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    The total number of subjects who withdrew from the study due to an adverse event irrespective of the causal relation between the AE and the study drug as determined by the investigator
  • Number of Subjects With Any Thrombotic or Thromboembolic Adverse Event During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    Examples include deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, central retinal artery and vein obstruction.
  • Number of Subjects Who Died During the Study [ Time Frame: Up to 27 menstrual cycles ] [ Designated as safety issue: Yes ]
    Number of subjects who died, for any reason, during the study
Safety through 12 months
Complete list of historical versions of study NCT00113568 on ClinicalTrials.gov Archive Site
Not Provided
Quality of life through 12 months
Not Provided
Not Provided
 
Safety Study of XP12B in Women With Menorrhagia
Multicenter Study to Evaluate the Safety of XP12B in Women With Heavy Menstrual Bleeding Associated With Menorrhagia

The purpose of this study is to evaluate the safety of XP12B in women with heavy menstrual bleeding associated with menorrhagia.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Menorrhagia
  • Heavy Menstrual Bleeding
Drug: Tranexamic acid tablets (XP12B)
Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
Other Names:
  • Lysteda
  • XP12B
  • tranexamic acid tablets
  • XP12B-MR
Experimental: XP12B (tranexamic acid tablets)
Intervention: Drug: Tranexamic acid tablets (XP12B)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
784
May 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women with menorrhagia
  • 18-49 years of age
  • Regularly occuring menstrual periods

Exclusion Criteria:

  • History or presence of clinically significant disease or abnormalities that might confound the study
  • History of bilateral oophorectomy or hysterectomy
Female
18 Years to 49 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00113568
XP12B-MR-302
Yes
Clinical Development Support, Ferring Pharmaceuticals
Ferring Pharmaceuticals
Not Provided
Study Director: Clinical Development Support Ferring Pharmaceuticals
Ferring Pharmaceuticals
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP